Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium

BMC Women's Health

Volumn 12, Issue , 2012, Pages

  Markowski, Dominique N ^a   Helmke, Burkhard M ^b,c   Radtke, Arlo ^a   Froeb, Jennifer ^a   Belge, Gazanfer ^a   Bartnitzke, Sabine ^a   Wosniok, Werner ^a   Czybulka Jachertz, Iris ^c   Deichert, Ulrich ^d   Bullerdiek, Jörn ^a,e  

^a UNIVERSITY OF BREMEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Elbe Kliniken   (Germany)

^d Krankenhaus Cuxhaven   (Germany)

^e UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

Apoptosis; Fibroids; Mdm2 antagonists; P14arf; Senescence

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; KI 67 ANTIGEN; NUTLIN 3; P21 ACTIVATED KINASE; PROTEIN BAX; PROTEIN MDM2; PROTEIN P53; IMIDAZOLE DERIVATIVE; MDM2 PROTEIN, HUMAN; PIPERAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYOMETRIUM; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; STUDENT T TEST; UTERUS MYOMA; WESTERN BLOTTING; ADULT; AGED; CELL AGING; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; LEIOMYOMA; METABOLISM; MIDDLE AGED; UTERUS CANCER;

ADULT; AGED; APOPTOSIS; CELL AGING; FEMALE; HUMANS; IMIDAZOLES; LEIOMYOMA; MIDDLE AGED; MYOMETRIUM; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 84855509642     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-12-2     Document Type: Article

References (20)

1. Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990, 94:435-438.
2. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003, 188:100-107.
3. Chia CC, Huang SC, Chen SS, Kang JY, Lin JC, Lin YS, Huang KF, Lee HJ, Zheng CC. Ultrasonographic evaluation of the change in uterine fibroids induced by treatment with a GnRH analog. Taiwan J Obstet Gynecol 2006, 45:124-128.
4. Matta WH, Shaw RW, Nye M. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin. Br J Obstet Gynaecol 1989, 96:200-206.
5. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001, CD000547.
6. Miller CE. Unmet therapeutic needs for uterine myomas. J Minim Invasive Gynecol 2009, 16:11-21.
7. Markowski DN, von Ahsen I, Nezhad MH, Wosniok W, Helmke BM, Bullerdiek J. HMGA2 and the p14Arf-TP53-CDKNIA Axis: A Delicate Balance in the Growth of Uterine Leiomyomas. Genes Chromosomes Cancer 2010, 49:661-668.
8. Lev Bar-Or R, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci USA 2000, 97:11250-11255.
9. Markowski DN, Helmke BM, Belge G, Nimzyk R, Bartnitzke S, Deichert U, Bullerdiek J. HMGA2 and p14Arf: Major Roles in Cellular Senescence of Fibroids and Therapeutic Implications. Anticancer Res 2011, 31:753-761.
10. Laser J, Lee P, Wei JJ. Cellular senescence in usual type uterine leiomyoma. Fertil Steril 2010, 93:2020-2026.
11. Klemke M, Meyer A, Nezhad MH, Bartnitzke S, Drieschner N, Frantzen C, Schmidt EH, Belge G, Bullerdiek J. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer 2009, 48:171-178.
12. Markowski DN, Helmke BM, Bullerdiek J. Cellular senescence in usual type uterine leiomyoma. Fertil Steril 2010, 94:e79. author reply e80.
13. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC, Robboy SJ. Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 2002, 441:53-62.
14. Jolma IW, Ni XY, Rensing L, Ruoff P. Harmonic oscillations in homeostatic controllers: Dynamics of the p53 regulatory system. Biophys J 2010, 98:743-752.
15. Proctor CJ, Gray DA. Explaining oscillations and variability in the p53-Mdm2 system. BMC Syst Biol 2008, 2:75.
16. Zaitseva M, Vollenhoven BJ, Rogers PA. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol Hum Reprod 2006, 12:187-207.
17. Stern C, Kazmierczak B, Thode B, Rommel B, Bartnitzke S, Dal Cin P, van de Ven W, Van den Berghe H, Bullerdiek J. Leiomyoma cells with 12q15 aberrations can be transformed in vitro and show a relatively stable karyotype during precrisis period. Cancer Genet Cytogenet 1991, 54:223-228.
18. Severino MF, Murray MJ, Brandon DD, Clinton GM, Burry KA, Novy MJ. Rapid loss of oestrogen and progesterone receptors in human leiomyoma and myometrial explant cultures. Mol Hum Reprod 1996, 2:823-828.
19. Gao Z, Matsuo H, Nakago S, Kurachi O, Maruo T. p53 Tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol. J Clin Endocrinol Metab 2002, 87:3915-3920.
20. An International System for Human Cytogenetic Nomenclature 2009, Basel, Switzerland: S. Karger, Shaffer LG, Slovak ML, Campbell LJ, ISCN.